Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
We show that variability in general levels of drug sensitivity in pre-clinical cancer models confounds biomarker discovery. However, using a very large panel of cell lines, each treated with many drugs, we could estimate a general level of sensitivity to all drugs in each cell line. By conditioning on this variable, biomarkers were identified that were more likely to be effective in clinical trials than those identified using a conventional uncorrected approach.